首页 > 最新文献

Physics and Imaging in Radiation Oncology最新文献

英文 中文
Prospective validation of a pretreatment 18F-FDG PET/CT and mean lung dose model for early radiation pneumonitis 18F-FDG预处理PET/CT和平均肺剂量模型对早期放射性肺炎的前瞻性验证
IF 3.3 Q2 ONCOLOGY Pub Date : 2025-10-01 DOI: 10.1016/j.phro.2025.100844
Maria Thor , Aditya Apte , Milan Grkovski , Charles B. Simone II , Daphna Y. Gelblum , Masoud Zarepisheh , Puneeth Iyengar , Abraham J. Wu , Jacob Y. Shin , Tafadzwa Chaunzwa , Jennifer Ma , David Billing , Mark Dunphy , Jamie E. Chaft , Daniel R. Gomez , Joseph O. Deasy , Narek Shaverdian

Background and purpose

Early onset radiation pneumonitis (RPEarly) after concurrent chemoradiotherapy (cCRT) can lead to consolidation immunotherapy (IO) discontinuation, and poor survival in locally advanced non-small cell lung cancer (LA-NSCLC). This work assessed the external validity of a previously published RPEarly risk model.

Material and methods

The RPEarly risk model utilizes pretreatment 18F-FDG PET/CT imaging of the normal lungs and the mean lung dose (MLD). The 90th percentile of the standardized uptake value (SUVP90) and the MLD model parameters from the previous derivation cohort (N = 160) were applied in the independent cohort (50 consecutive LA-NSCLC patients treated with cCRT and IO) where model performance was evaluated (area under the receiver-operating characteristic curve (AUC), p-values, and the Hosmer-Lemeshow test (pHL)).

Results

Seven patients (14 %) developed RPEarly. Model performance of the previously developed SUVP90 and MLD model improved with re-fitting (AUC = 0.76 vs. 0.72; p = 0.01 vs. 0.10; pHL = 0.66 vs. 0.94). Above a clinically desirable 10 % predicted RPEarly, after refitting model coefficients in the combined derivation and validation cohorts (N = 210), the MLD was 13 ± 2.2 EQD23 Gy (SUVP90 = 1.2 ± 0.3) above the RPEarly risk threshold vs. 8.5 ± 2.6 EQD23 Gy (0.9 ± 0.2) below the threshold. For an SUVP90 of 1.1 and an MLD of 11 Gy EQD23 Gy, 25/27 patients developing RPEarly were captured.

Conclusion

The previously developed SUVP90 and MLD-based risk model for RPEarly demonstrated a high probability to correctly predict RPEarly in the independent cohort. This now validated RPEarly risk model with derived high-risk indications could enable personalized thoracic RT planning to reduce the risk of RPEarly and of discontinuing life-prolonging IO post-cCRT.
背景和目的同步放化疗(cCRT)后早发性放射性肺炎(RPEarly)可导致局部晚期非小细胞肺癌(LA-NSCLC)的巩固免疫治疗(IO)中断和生存率低。这项工作评估了先前发表的RPEarly风险模型的外部有效性。材料和方法RPEarly risk模型采用预处理的18F-FDG PET/CT正常肺成像和平均肺剂量(MLD)。在独立队列(50例连续接受cCRT和IO治疗的LA-NSCLC患者)中,采用标准化摄取值(SUVP90)的第90百分位和先前衍生队列(N = 160)的MLD模型参数,评估模型性能(接受者-工作特征曲线下面积(AUC)、p值和Hosmer-Lemeshow检验(pHL))。结果早期发病7例(14%)。先前开发的SUVP90和MLD模型的模型性能通过重新拟合得到改善(AUC = 0.76 vs. 0.72; p = 0.01 vs. 0.10; pHL = 0.66 vs. 0.94)。在推导和验证联合队列(N = 210)中修正模型系数后,在临床所需的10%以上预测RPEarly, MLD比RPEarly风险阈值高13±2.2 EQD23 Gy (SUVP90 = 1.2±0.3),比阈值低8.5±2.6 EQD23 Gy(0.9±0.2)。SUVP90为1.1,MLD为11 Gy EQD23 Gy,捕获了25/27的早期发展患者。结论先前建立的基于SUVP90和mld的RPEarly风险模型在独立队列中正确预测RPEarly的概率很高。现在,这个经过验证的RPEarly风险模型及其衍生的高风险适应症可以实现个性化的胸部RT计划,以降低RPEarly的风险和ccrt后停止延长生命的IO的风险。
{"title":"Prospective validation of a pretreatment 18F-FDG PET/CT and mean lung dose model for early radiation pneumonitis","authors":"Maria Thor ,&nbsp;Aditya Apte ,&nbsp;Milan Grkovski ,&nbsp;Charles B. Simone II ,&nbsp;Daphna Y. Gelblum ,&nbsp;Masoud Zarepisheh ,&nbsp;Puneeth Iyengar ,&nbsp;Abraham J. Wu ,&nbsp;Jacob Y. Shin ,&nbsp;Tafadzwa Chaunzwa ,&nbsp;Jennifer Ma ,&nbsp;David Billing ,&nbsp;Mark Dunphy ,&nbsp;Jamie E. Chaft ,&nbsp;Daniel R. Gomez ,&nbsp;Joseph O. Deasy ,&nbsp;Narek Shaverdian","doi":"10.1016/j.phro.2025.100844","DOIUrl":"10.1016/j.phro.2025.100844","url":null,"abstract":"<div><h3>Background and purpose</h3><div>Early onset radiation pneumonitis (RP<sub>Early</sub>) after concurrent chemoradiotherapy (cCRT) can lead to consolidation immunotherapy (IO) discontinuation, and poor survival in locally advanced non-small cell lung cancer (LA-NSCLC). This work assessed the external validity of a previously published RP<sub>Early</sub> risk model.</div></div><div><h3>Material and methods</h3><div>The RP<sub>Early</sub> risk model utilizes pretreatment 18F-FDG PET/CT imaging of the normal lungs and the mean lung dose (MLD). The 90th percentile of the standardized uptake value (SUV<sub>P90</sub>) and the MLD model parameters from the previous derivation cohort (N = 160) were applied in the independent cohort (50 consecutive LA-NSCLC patients treated with cCRT and IO) where model performance was evaluated (area under the receiver-operating characteristic curve (AUC), <em>p-values</em>, and the Hosmer-Lemeshow test (<em>pHL</em>)).</div></div><div><h3>Results</h3><div>Seven patients (14 %) developed RP<sub>Early</sub>. Model performance of the previously developed SUV<sub>P90</sub> and MLD model improved with re-fitting (AUC = 0.76 <em>vs.</em> 0.72; p = 0.01 <em>vs.</em> 0.10; pHL = 0.66 <em>vs.</em> 0.94). Above a clinically desirable 10 % predicted RP<sub>Early</sub>, after refitting model coefficients in the combined derivation and validation cohorts (N = 210), the MLD was 13 ± 2.2 EQD2<sub>3</sub> Gy (SUV<sub>P90</sub> = 1.2 ± 0.3) above the RP<sub>Early</sub> risk threshold <em>vs.</em> 8.5 ± 2.6 EQD2<sub>3</sub> Gy (0.9 ± 0.2) below the threshold. For an SUV<sub>P90</sub> of 1.1 and an MLD of 11 Gy EQD2<sub>3</sub> Gy, 25/27 patients developing RP<sub>Early</sub> were captured.</div></div><div><h3>Conclusion</h3><div>The previously developed SUV<sub>P90</sub> and MLD-based risk model for RP<sub>Early</sub> demonstrated a high probability to correctly predict RP<sub>Early</sub> in the independent cohort. This now validated RP<sub>Early</sub> risk model with derived high-risk indications could enable personalized thoracic RT planning to reduce the risk of RP<sub>Early</sub> and of discontinuing life-prolonging IO post-cCRT.</div></div>","PeriodicalId":36850,"journal":{"name":"Physics and Imaging in Radiation Oncology","volume":"36 ","pages":"Article 100844"},"PeriodicalIF":3.3,"publicationDate":"2025-10-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145221817","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Leveraging dixon-based magnetic resonance imaging for pelvic bone marrow imaging in radiotherapy 利用基于dixon的磁共振成像在放射治疗中的盆腔骨髓成像
IF 3.3 Q2 ONCOLOGY Pub Date : 2025-10-01 DOI: 10.1016/j.phro.2025.100841
Chuyan Wang , Haoping Xu , Zhenkui Wang , Li Tong , Xijing Zhang , Fuhua Yan , Jiayi Chen , Yingli Yang

Background and purpose

Pelvic radiotherapy-induced bone marrow (BM) damage adversely affects patient prognosis. Progress in BM-sparing radiotherapy is limited by the lack of standardized BM quantification and the inherent constraints of magnetic resonance spectroscopy (MRS), the current gold standard for BM magnetic resonance imaging (MRI). Proton density fat fraction (PDFF), derived from DIXON-based MRI, has emerged as an imaging biomarker for detecting BM changes. This study evaluated the potential of DIXON-based MRI in pelvic BM for radiotherapy.

Materials and methods

Three existing DIXON-based techniques were optimized and compared to establish clinical protocols. In vitro measurements were performed using fat phantoms calibrated against thermogravimetric analysis, while in vivo measurements were based on data from 30 volunteers with MRS serving as the reference standard. Quantitative accuracy was assessed using mean absolute error (MAE), repeatability via intra-class correlation coefficients (ICCs), and image quality using an ACR phantom.

Results

Comprehensive evaluation identified optimal parameters for each DIXON-based sequence. For in vitro measurements, the MAE for MRS was 3.5 % and the highest MAE across three optimized DIXON-based sequences was 5.9 %. For in vivo measurements, linear regressions between MRS and each of the optimized DIXON-based sequence resulted in R2 ≥ 0.93 and MAE ≤ 7.6 %. All three optimized DIXON-based sequences demonstrated high repeatability (ICCs ≥ 0.97) and clearly visualized BM with varying fat fractions, with no consistently outperforming in image quality.

Conclusion

For BM assessment, this study demonstrated DIXON-based PDFF quantification achieved high accuracy, repeatability, and image quality, supporting its potential for radiotherapy.
背景与目的盆腔放疗所致的骨髓损伤对患者预后有不利影响。保留脑基放射治疗的进展受到缺乏标准化脑基量化和磁共振波谱(MRS)固有约束的限制,磁共振波谱是目前脑基磁共振成像(MRI)的金标准。质子密度脂肪分数(PDFF)源于基于dixon的MRI,已成为检测BM变化的成像生物标志物。本研究评估了DIXON-based MRI在骨盆BM放射治疗中的潜力。材料与方法对现有的三种基于dixon的技术进行优化和比较,建立临床方案。体外测量使用根据热重分析校准的脂肪模型进行,而体内测量基于30名志愿者的数据,以MRS作为参考标准。使用平均绝对误差(MAE)评估定量准确性,通过类内相关系数(icc)评估重复性,使用ACR模型评估图像质量。结果综合评价确定了各dixon序列的最优参数。对于体外测量,MRS的MAE为3.5%,三个优化的基于dixon的序列的最高MAE为5.9%。在体内测量中,MRS与每个优化的基于dixon的序列之间的线性回归结果为R2≥0.93,MAE≤7.6%。所有三个优化的基于dixon的序列都具有高重复性(ICCs≥0.97),并且清晰地显示了不同脂肪含量的BM,并且在图像质量上没有一致的表现。结论本研究表明,基于dixon的PDFF定量方法具有较高的准确性、重复性和图像质量,支持其在放疗中的潜力。
{"title":"Leveraging dixon-based magnetic resonance imaging for pelvic bone marrow imaging in radiotherapy","authors":"Chuyan Wang ,&nbsp;Haoping Xu ,&nbsp;Zhenkui Wang ,&nbsp;Li Tong ,&nbsp;Xijing Zhang ,&nbsp;Fuhua Yan ,&nbsp;Jiayi Chen ,&nbsp;Yingli Yang","doi":"10.1016/j.phro.2025.100841","DOIUrl":"10.1016/j.phro.2025.100841","url":null,"abstract":"<div><h3>Background and purpose</h3><div>Pelvic radiotherapy-induced bone marrow (BM) damage adversely affects patient prognosis. Progress in BM-sparing radiotherapy is limited by the lack of standardized BM quantification and the inherent constraints of magnetic resonance spectroscopy (MRS), the current gold standard for BM magnetic resonance imaging (MRI). Proton density fat fraction (PDFF), derived from DIXON-based MRI, has emerged as an imaging biomarker for detecting BM changes. This study evaluated the potential of DIXON-based MRI in pelvic BM for radiotherapy.</div></div><div><h3>Materials and methods</h3><div>Three existing DIXON-based techniques were optimized and compared to establish clinical protocols. <em>In vitro</em> measurements were performed using fat phantoms calibrated against thermogravimetric analysis, while <em>in vivo</em> measurements were based on data from 30 volunteers with MRS serving as the reference standard. Quantitative accuracy was assessed using mean absolute error (MAE), repeatability via intra-class correlation coefficients (ICCs), and image quality using an ACR phantom.</div></div><div><h3>Results</h3><div>Comprehensive evaluation identified optimal parameters for each DIXON-based sequence. For <em>in vitro</em> measurements, the MAE for MRS was 3.5 % and the highest MAE across three optimized DIXON-based sequences was 5.9 %. For <em>in vivo</em> measurements, linear regressions between MRS and each of the optimized DIXON-based sequence resulted in R<sup>2</sup> ≥ 0.93 and MAE ≤ 7.6 %. All three optimized DIXON-based sequences demonstrated high repeatability (ICCs ≥ 0.97) and clearly visualized BM with varying fat fractions, with no consistently outperforming in image quality.</div></div><div><h3>Conclusion</h3><div>For BM assessment, this study demonstrated DIXON-based PDFF quantification achieved high accuracy, repeatability, and image quality, supporting its potential for radiotherapy.</div></div>","PeriodicalId":36850,"journal":{"name":"Physics and Imaging in Radiation Oncology","volume":"36 ","pages":"Article 100841"},"PeriodicalIF":3.3,"publicationDate":"2025-10-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145221820","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
New modalities for ultra-high dose rate irradiation and FLASH experiments 超高剂量率辐照和FLASH实验的新模式
IF 3.3 Q2 ONCOLOGY Pub Date : 2025-10-01 DOI: 10.1016/j.phro.2025.100861
Gabriel Adrian, Raphaël Moeckli, Elke Beyreuther, Ludvig P. Muren, Brita Singers Sørensen
{"title":"New modalities for ultra-high dose rate irradiation and FLASH experiments","authors":"Gabriel Adrian,&nbsp;Raphaël Moeckli,&nbsp;Elke Beyreuther,&nbsp;Ludvig P. Muren,&nbsp;Brita Singers Sørensen","doi":"10.1016/j.phro.2025.100861","DOIUrl":"10.1016/j.phro.2025.100861","url":null,"abstract":"","PeriodicalId":36850,"journal":{"name":"Physics and Imaging in Radiation Oncology","volume":"36 ","pages":"Article 100861"},"PeriodicalIF":3.3,"publicationDate":"2025-10-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145466706","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
First implementation of photon-counting dector computed tomography for optimizing segmentation in head-and-neck cancer radiotherapy 首次实现光子计数检测器计算机断层扫描优化头颈部肿瘤放疗的分割
IF 3.3 Q2 ONCOLOGY Pub Date : 2025-10-01 DOI: 10.1016/j.phro.2025.100864
Niccolò Bertini , Hubert S. Gabryś , Hatem Alkadhi , Lotte Wilke , Patrick Wohlfahrt , Serena Psoroulas , Eugenia Vlaskou , Laura Motisi , Matthias Guckenberger , Stephanie Tanadini-Lang , Panagiotis Balermpas

Background and purpose

Photon-counting detector computed tomography (PCD-CT) offers advancements over conventional energy-integrating detector computed tomography (EID-CT). This study is the first to investigate the use of PCD-CT for delineation purposes.

Materials and methods

Twelve patients with head-and-neck cancer were prospectively included. Delineation of clinical target volume (CTV) and organs at risk (OARs) was performed by three physicians using EID-CT (120 kVp) and PCD-CT at virtual monoenergetic levels of 140 keV and 50 keV. Segmentation accuracy was assessed and contouring-confidence was rated.

Results

The ratio of the mean computed tomography dose index (CTDI) for EID-CT/PCD-CT for all patients was 2.72. The study revealed high inter-observer agreement for the mandible, oral cavity, parotid glands, and submandibular glands, with DSCs exceeding 0.8 across both EID-CT and PCD-CT. No differences in delineation agreement were observed, while a significant improvement was found for the lips (p = 0.001) and oral cavity (p = 0.003) when combining 140  keV and 50  keV images in PCD-CT compared to EID-CT. PCD-CT outperformed EID-CT in terms of contouring confidence.

Conclusion

The study established the feasibility of PCD-CT for radiotherapy planning. PCD-CT-based delineation provides results comparable to EID-CT, with the added advantages of reduced radiation dose, improved image quality and higher delineation confidence. Significant improvements in delineating specific structures, such as the lips and oral cavity, were observed when combining multiple energy levels in PCD-CT.
背景和目的光子计数检测器计算机断层扫描(PCD-CT)是传统能量积分检测器计算机断层扫描(EID-CT)的进步。本研究首次探讨了利用PCD-CT进行圈定的目的。材料与方法前瞻性纳入12例头颈癌患者。临床靶体积(CTV)和危险器官(OARs)由三名医生在140 keV和50 keV的虚拟单能水平下使用EID-CT (120 kVp)和PCD-CT进行描绘。评估分割精度和轮廓置信度。结果所有患者的EID-CT/PCD-CT平均ct剂量指数(CTDI)之比为2.72。该研究显示,下颌骨、口腔、腮腺和下颌下腺的观察者间一致性很高,在EID-CT和PCD-CT上,dsc均超过0.8。与EID-CT相比,结合140 keV和50 keV的PCD-CT图像,发现嘴唇(p = 0.001)和口腔(p = 0.003)的描画一致性没有差异。在轮廓置信度方面,PCD-CT优于EID-CT。结论本研究确立了PCD-CT辅助放疗规划的可行性。基于pcd - ct的成像结果可与EID-CT媲美,并且具有辐射剂量降低、图像质量改善和成像可信度更高的优点。在PCD-CT结合多个能量水平时,观察到在描绘特定结构(如嘴唇和口腔)方面有显着改善。
{"title":"First implementation of photon-counting dector computed tomography for optimizing segmentation in head-and-neck cancer radiotherapy","authors":"Niccolò Bertini ,&nbsp;Hubert S. Gabryś ,&nbsp;Hatem Alkadhi ,&nbsp;Lotte Wilke ,&nbsp;Patrick Wohlfahrt ,&nbsp;Serena Psoroulas ,&nbsp;Eugenia Vlaskou ,&nbsp;Laura Motisi ,&nbsp;Matthias Guckenberger ,&nbsp;Stephanie Tanadini-Lang ,&nbsp;Panagiotis Balermpas","doi":"10.1016/j.phro.2025.100864","DOIUrl":"10.1016/j.phro.2025.100864","url":null,"abstract":"<div><h3>Background and purpose</h3><div>Photon-counting detector computed tomography (PCD-CT) offers advancements over conventional energy-integrating detector computed tomography (EID-CT). This study is the first to investigate the use of PCD-CT for delineation purposes.</div></div><div><h3>Materials and methods</h3><div>Twelve patients with head-and-neck cancer were prospectively included. Delineation of clinical target volume (CTV) and organs at risk (OARs) was performed by three physicians using EID-CT (120 kVp) and PCD-CT at virtual monoenergetic levels of 140 keV and 50 keV. Segmentation accuracy was assessed and contouring-confidence was rated.</div></div><div><h3>Results</h3><div>The ratio of the mean computed tomography dose index (CTDI) for EID-CT/PCD-CT for all patients was 2.72. The study revealed high inter-observer agreement for the mandible, oral cavity, parotid glands, and submandibular glands, with DSCs exceeding 0.8 across both EID-CT and PCD-CT. No differences in delineation agreement were observed, while a significant improvement was found for the lips (p = 0.001) and oral cavity (p = 0.003) when combining 140  keV and 50  keV images in PCD-CT compared to EID-CT. PCD-CT outperformed EID-CT in terms of contouring confidence.</div></div><div><h3>Conclusion</h3><div>The study established the feasibility of PCD-CT for radiotherapy planning. PCD-CT-based delineation provides results comparable to EID-CT, with the added advantages of reduced radiation dose, improved image quality and higher delineation confidence. Significant improvements in delineating specific structures, such as the lips and oral cavity, were observed when combining multiple energy levels in PCD-CT.</div></div>","PeriodicalId":36850,"journal":{"name":"Physics and Imaging in Radiation Oncology","volume":"36 ","pages":"Article 100864"},"PeriodicalIF":3.3,"publicationDate":"2025-10-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145614338","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
A cone-beam computed tomography based workflow for online adaptive ultra-hypofractionated radiotherapy of prostate cancer 基于锥束计算机断层的前列腺癌在线自适应超低分割放疗工作流程
IF 3.3 Q2 ONCOLOGY Pub Date : 2025-10-01 DOI: 10.1016/j.phro.2025.100869
Miriam Eckl , Nour Alfakhori , Marvin Willam , Hans Oppitz , Constantin Dreher , Michael Ehmann , Judit Boda-Heggemann , Frank A. Giordano , Jens Fleckenstein

Background and purpose

Cone beam computed tomography (CBCT)-based approaches for online adaptive radiation therapy (oART) have recently become clinically available for ultra-hypofractionated prostate stereotactic body radiation therapy (SBRT). This work assessed the changes of relevant dose-volume-histogram (DVH) parameters and their robustness against morphologic variations during adaptation.

Materials and methods

Sixteen prostate cancer patients were treated with oART in an SBRT regimen (40 Gy in 5 treatment sessions (Tx) to the clinical target volume (CTV), PACE-B constraints). Two CBCTs were acquired daily: CBCT1 for adaptive planning and CBCT2 after adaptation for position verification. Adapted plans optimized on CBCT1 (ARTCBCT1) were recalculated on CBCT2 (ARTCBCT2) and compared to treatment plans on CBCT1 after image guidance (IGRTCBCT1) for relevant DVH metrics: V40Gy(CTV), V37Gy(bladder), V36Gy(rectum). Spearman’s rank coefficients r with p-values (5% significance level) were determined to analyze correlations between adaptation time (ΔT) and bladder filling as well as Tx and median prostate volume.

Results

oART improved median V40Gy(CTV) from 86% in IGRTCBCT1 to 94% in ARTCBCT2. Inter-fractional prostate swelling (rTx,Vol(prostate)=0.98,p=0.005) was responsible for CTV deviations. Bladder filling (rΔT,Vol(bladder)=0.34,p=0.002) and rectal gas migration during the median adaptation time ΔT=24.0min increased V37Gy(bladder) from 4.9 cm3 in ARTCBCT1 to 6.5 cm3 in ARTCBCT2 and V36Gy(rectum) from 0.5 cm3 to 0.6 cm3 and led to 10 constraint violations, each.

Conclusion

Compared to IGRT, daily oART substantially improved CTV coverage. Besides inter-fractional prostate swelling, constraint violations originated from seminal vesicles motion, rectal gas or bladder filling during adaptation. Treatment adaptation times should therefore be minimized whenever possible.
背景和目的基于CBCT的在线适应性放射治疗(oART)方法最近已成为超低分割前列腺立体定向放射治疗(SBRT)的临床应用。本研究评估了相关剂量-体积-直方图(DVH)参数的变化及其对适应过程中形态变化的鲁棒性。材料和方法16例前列腺癌患者接受oART治疗,采用SBRT方案(5个疗程(Tx) 40 Gy至临床靶体积(CTV), PACE-B限制)。每天获取两个cbct: CBCT1用于自适应规划,CBCT2用于位置验证。在CBCT1上优化的适应方案(ARTCBCT1)在CBCT2 (ARTCBCT2)上重新计算,并与图像引导后CBCT1的治疗方案(IGRTCBCT1)进行相关DVH指标的比较:V40Gy(CTV), V37Gy(膀胱),V36Gy(直肠)。测定Spearman秩系数r, p值为5%(显著性水平),分析适应时间(ΔT)与膀胱充盈、Tx和中位前列腺体积之间的相关性。结果art将中位V40Gy(CTV)从IGRTCBCT1的86%提高到ARTCBCT2的94%。分数阶间前列腺肿胀(rTx,Vol(前列腺)=0.98,p=0.005)是CTV偏差的主要原因。膀胱充盈(rΔT,Vol(膀胱)=0.34,p=0.002)和直肠气体迁移在中位适应时间ΔT=24.0min内使V37Gy(膀胱)从ARTCBCT1的4.9 cm3增加到ARTCBCT2的6.5 cm3, V36Gy(直肠)从0.5 cm3增加到0.6 cm3,各导致10次约束违规。结论与IGRT相比,每日oART显著提高了CTV覆盖率。除前列腺分段间肿胀外,适应过程中精囊运动、直肠充气或膀胱充盈也会导致约束违规。因此,应尽可能缩短治疗适应时间。
{"title":"A cone-beam computed tomography based workflow for online adaptive ultra-hypofractionated radiotherapy of prostate cancer","authors":"Miriam Eckl ,&nbsp;Nour Alfakhori ,&nbsp;Marvin Willam ,&nbsp;Hans Oppitz ,&nbsp;Constantin Dreher ,&nbsp;Michael Ehmann ,&nbsp;Judit Boda-Heggemann ,&nbsp;Frank A. Giordano ,&nbsp;Jens Fleckenstein","doi":"10.1016/j.phro.2025.100869","DOIUrl":"10.1016/j.phro.2025.100869","url":null,"abstract":"<div><h3>Background and purpose</h3><div>Cone beam computed tomography (CBCT)-based approaches for online adaptive radiation therapy (oART) have recently become clinically available for ultra-hypofractionated prostate stereotactic body radiation therapy (SBRT). This work assessed the changes of relevant dose-volume-histogram (DVH) parameters and their robustness against morphologic variations during adaptation.</div></div><div><h3>Materials and methods</h3><div>Sixteen prostate cancer patients were treated with oART in an SBRT regimen (40<!--> <!-->Gy in 5 treatment sessions (Tx) to the clinical target volume (CTV), PACE-B constraints). Two CBCTs were acquired daily: CBCT1 for adaptive planning and CBCT2 after adaptation for position verification. Adapted plans optimized on CBCT1 (ART<sub>CBCT1</sub>) were recalculated on CBCT2 (ART<sub>CBCT2</sub>) and compared to treatment plans on CBCT1 after image guidance (IGRT<sub>CBCT1</sub>) for relevant DVH metrics: V<sub>40Gy</sub>(CTV), V<sub>37Gy</sub>(bladder), V<sub>36Gy</sub>(rectum). Spearman’s rank coefficients r with p-values (5% significance level) were determined to analyze correlations between adaptation time (ΔT) and bladder filling as well as Tx and median prostate volume.</div></div><div><h3>Results</h3><div>oART improved median V<sub>40Gy</sub>(CTV) from 86% in IGRT<sub>CBCT1</sub> to 94% in ART<sub>CBCT2</sub>. Inter-fractional prostate swelling (<span><math><mrow><msub><mi>r</mi><mrow><mi>T</mi><mi>x</mi><mo>,</mo><mi>V</mi><mi>o</mi><mi>l</mi><mo>(</mo><mi>p</mi><mi>r</mi><mi>o</mi><mi>s</mi><mi>t</mi><mi>a</mi><mi>t</mi><mi>e</mi><mo>)</mo></mrow></msub><mrow><mo>=</mo><mn>0.98</mn><mo>,</mo><mi>p</mi><mo>=</mo><mn>0.005</mn><mo>)</mo></mrow></mrow></math></span> was responsible for CTV deviations. Bladder filling (<span><math><mrow><msub><mi>r</mi><mrow><mi>Δ</mi><mi>T</mi><mo>,</mo><mi>V</mi><mi>o</mi><mi>l</mi><mo>(</mo><mi>b</mi><mi>l</mi><mi>a</mi><mi>d</mi><mi>d</mi><mi>e</mi><mi>r</mi><mo>)</mo></mrow></msub><mo>=</mo><mn>0.34</mn><mo>,</mo><mi>p</mi><mo>=</mo><mn>0.002</mn></mrow></math></span>) and rectal gas migration during the median adaptation time <span><math><mrow><mi>Δ</mi><mi>T</mi><mo>=</mo><mn>24.0</mn><mspace></mspace><mi>m</mi><mi>i</mi><mi>n</mi></mrow></math></span> increased V<sub>37Gy</sub>(bladder) from 4.9 cm<sup>3</sup> in ART<sub>CBCT1</sub> to 6.5 cm<sup>3</sup> in ART<sub>CBCT2</sub> and V<sub>36Gy</sub>(rectum) from 0.5 cm<sup>3</sup> to 0.6 cm<sup>3</sup> and led to 10 constraint violations, each.</div></div><div><h3>Conclusion</h3><div>Compared to IGRT, daily oART substantially improved CTV coverage. Besides inter-fractional prostate swelling, constraint violations originated from seminal vesicles motion, rectal gas or bladder filling during adaptation. Treatment adaptation times should therefore be minimized whenever possible.</div></div>","PeriodicalId":36850,"journal":{"name":"Physics and Imaging in Radiation Oncology","volume":"36 ","pages":"Article 100869"},"PeriodicalIF":3.3,"publicationDate":"2025-10-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145576374","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Proton radiography interpretation with artificial intelligence for treatment deviation detection in proton therapy 人工智能在质子治疗中诊断治疗偏差的质子x线解译
IF 3.3 Q2 ONCOLOGY Pub Date : 2025-10-01 DOI: 10.1016/j.phro.2025.100872
Giuliano Perotti Bernardini, Arthur Galapon, Gabriel Guterres Marmitt, Jeffrey Free, Peter van Ooijen, Johannes Langendijk, Stefan Both

Background and purpose

Patient setup errors, anatomical changes, and uncertainties in proton range estimation degrade dose conformity in proton therapy. Adaptive proton therapy (APT) mitigates these deviations by monitoring and adjusting treatment plans. Proton radiography (PR) offers direct proton range information, making it a promising method to detect such deviations. In this study, we developed and evaluated an artificial intelligence (AI) PR tool for automated interpretation and classification of treatment deviations.

Materials and methods

Computed Tomography (CT) scans from 32 head-and-neck cancer patients were synthetically modified to simulate setup errors (±2–4 mm), calibration curve errors (±3–5% for fat/soft tissue, ±7–11% for bone), and anatomical changes (±2–12 mm mimicking weight variations). PR simulations were performed using OpenREGGUI to generate integral depth dose (IDD) curves and range shift maps (RSMs) across 260 × 260 mm2 PR fields, resulting in 14,503 RSMs. A convolutional neural network (EfficientNet-v2-M) was trained from scratch for multi-label classification. Performance was evaluated on the synthetic dataset and an independent clinical dataset of 22 patients who underwent plan adaptation.

Results

The CNN classified treatment deviations within one second per image. On the synthetic dataset, it achieved 97% precision, 92% recall, 93% F1-score, and 92% F2-score. On the clinical validation set, it maintained high performance metrics: 86% precision, 88% recall, 86% F1-score, and 87% F2-score, demonstrating strong generalization to clinical scenarios.

Conclusions

The AI-enhanced PR tool enables fast, automated detection of treatment deviations in proton therapy, supporting its integration into APT workflows and online plan adaptation for improved quality assurance.
背景与目的:患者设置错误、解剖改变和质子范围估计的不确定性降低了质子治疗的剂量一致性。适应性质子治疗(APT)通过监测和调整治疗计划来减轻这些偏差。质子放射照相(PR)提供了直接的质子范围信息,使其成为一种很有前途的检测这种偏差的方法。在本研究中,我们开发并评估了用于自动解释和分类治疗偏差的人工智能(AI) PR工具。材料和方法对32例头颈癌患者的CT扫描进行综合修改,模拟设置误差(±2-4 mm)、校准曲线误差(脂肪/软组织±3-5%,骨骼±7-11%)和解剖变化(±2-12 mm模拟体重变化)。利用OpenREGGUI进行PR模拟,生成260 × 260 mm2 PR场的积分深度剂量(IDD)曲线和距离位移图(rsm),得到14503个rsm。从头开始训练卷积神经网络(EfficientNet-v2-M)进行多标签分类。在合成数据集和22名接受计划适应的患者的独立临床数据集上评估性能。结果CNN能在1秒内对每幅图像的处理偏差进行分类。在合成数据集上,它达到了97%的精度,92%的召回率,93%的f1得分和92%的f2得分。在临床验证集上,它保持了很高的性能指标:86%的准确率,88%的召回率,86%的f1得分和87%的f2得分,显示出对临床场景的强泛化。人工智能增强的PR工具可以快速、自动地检测质子治疗的治疗偏差,支持其集成到APT工作流程和在线计划调整中,以提高质量保证。
{"title":"Proton radiography interpretation with artificial intelligence for treatment deviation detection in proton therapy","authors":"Giuliano Perotti Bernardini,&nbsp;Arthur Galapon,&nbsp;Gabriel Guterres Marmitt,&nbsp;Jeffrey Free,&nbsp;Peter van Ooijen,&nbsp;Johannes Langendijk,&nbsp;Stefan Both","doi":"10.1016/j.phro.2025.100872","DOIUrl":"10.1016/j.phro.2025.100872","url":null,"abstract":"<div><h3>Background and purpose</h3><div>Patient setup errors, anatomical changes, and uncertainties in proton range estimation degrade dose conformity in proton therapy. Adaptive proton therapy (APT) mitigates these deviations by monitoring and adjusting treatment plans. Proton radiography (PR) offers direct proton range information, making it a promising method to detect such deviations. In this study, we developed and evaluated an artificial intelligence (AI) PR tool for automated interpretation and classification of treatment deviations.</div></div><div><h3>Materials and methods</h3><div>Computed Tomography (CT) scans from 32 head-and-neck cancer patients were synthetically modified to simulate setup errors (±2–4 mm), calibration curve errors (±3–5% for fat/soft tissue, ±7–11% for bone), and anatomical changes (±2–12 mm mimicking weight variations). PR simulations were performed using OpenREGGUI to generate integral depth dose (IDD) curves and range shift maps (RSMs) across 260 × 260 mm<sup>2</sup> PR fields, resulting in 14,503 RSMs. A convolutional neural network (EfficientNet-v2-M) was trained from scratch for multi-label classification. Performance was evaluated on the synthetic dataset and an independent clinical dataset of 22 patients who underwent plan adaptation.</div></div><div><h3>Results</h3><div>The CNN classified treatment deviations within one second per image. On the synthetic dataset, it achieved 97% precision, 92% recall, 93% F1-score, and 92% F2-score. On the clinical validation set, it maintained high performance metrics: 86% precision, 88% recall, 86% F1-score, and 87% F2-score, demonstrating strong generalization to clinical scenarios.</div></div><div><h3>Conclusions</h3><div>The AI-enhanced PR tool enables fast, automated detection of treatment deviations in proton therapy, supporting its integration into APT workflows and online plan adaptation for improved quality assurance.</div></div>","PeriodicalId":36850,"journal":{"name":"Physics and Imaging in Radiation Oncology","volume":"36 ","pages":"Article 100872"},"PeriodicalIF":3.3,"publicationDate":"2025-10-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145681035","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Integrating automated electromagnetic tracking-based needle reconstruction in the intraoperative high-dose-rate prostate brachytherapy workflow 在术中高剂量率前列腺近距离放射治疗工作流程中集成基于自动电磁跟踪的针头重建
IF 3.3 Q2 ONCOLOGY Pub Date : 2025-10-01 DOI: 10.1016/j.phro.2025.100884
Ioannis Androulakis , Jérémy Godart , Miranda E.M.C. Christianen , Henrike Westerveld , Lorne Luthart , Remi A. Nout , Mischa S. Hoogeman , Inger-Karine K. Kolkman-Deurloo

Background and Purpose

Manual transrectal ultrasound (TRUS) reconstruction, currently used in intraoperative prostate brachytherapy, is error‑prone. Automated implant reconstruction with electromagnetic tracking (EMT) has the potential to improve accuracy. The aim of this study was to implement and validate afterloader‑integrated EMT for automated implant reconstruction.

Materials and Methods

An afterloader prototype equipped with an integrated EMT system was used in conjunction with a TRUS-based treatment planning system and setup. A workflow was developed to transform the EMT measurements into the implant reconstruction and import this into the treatment planning software. The workflow was retrospectively evaluated using clinical data from 14 patients. To align the EMT measurements with the treatment-planning coordinate system without a TRUS-based pre-reconstruction, a novel setup was developed using a single reference sensor integrated into the template holder. The reproducibility and accuracy of the workflow using this latter setup was evaluated in phantom measurements.

Results

The retrospective evaluation revealed that errors in active dwell positions of up to 10.2 mm caused absolute V100% differences of up to 5.3 % of the target volume, and up to 24.4 %, 2.1 %, and 14.1 % of the prescribed dose for urethra D0.1cm3, rectum D2cm3, and bladder D1cm3, respectively. In phantom measurements with our novel setup using reference sensor registration, EMT-based reconstruction demonstrated high reproducibility (0.5 mm) and agreement with TRUS-based reconstruction (0.7 mm), requiring a measurement time of < 23 s per implanted needle.

Conclusion

The implementation of EMT-based reconstruction on clinical data shows clinically relevant impact on dose-volume metrics of TRUS-based implant reconstructions errors. Using the novel workflow and hardware, highly accurate and automated implant reconstruction is possible.
背景与目的经直肠超声(TRUS)重建术,目前用于术中前列腺近距离治疗,容易出错。采用电磁跟踪(EMT)的自动植入体重建具有提高准确性的潜力。本研究的目的是实施和验证后装载机集成EMT用于自动种植体重建。材料和方法配备了集成EMT系统的后置装载机原型机与基于tri的处理计划系统和设置一起使用。开发了一个工作流程,将EMT测量转换为植入物重建,并将其导入治疗计划软件。使用14例患者的临床资料对该工作流程进行回顾性评估。为了使EMT测量值与治疗计划坐标系对齐,无需基于tri的预重建,开发了一种新型装置,使用集成在模板支架中的单个参考传感器。使用后一种设置的工作流程的再现性和准确性在模拟测量中进行了评估。结果回顾性评价结果显示,活性驻留位置误差(最大10.2 mm)导致的靶体积绝对V100%差异高达5.3%,尿道D0.1cm3、直肠D2cm3和膀胱D1cm3分别高达24.4%、2.1%和14.1%的处方剂量差异。在我们使用参考传感器配准的新装置进行的假体测量中,基于emt的重建显示出高再现性(0.5 mm),并且与基于trt的重建(0.7 mm)一致,每根植入针需要23秒的测量时间。结论基于emt的种植体重建对临床数据的实施对基于trt的种植体重建误差的剂量-体积指标有临床相关的影响。使用新的工作流程和硬件,高度精确和自动化的植入物重建是可能的。
{"title":"Integrating automated electromagnetic tracking-based needle reconstruction in the intraoperative high-dose-rate prostate brachytherapy workflow","authors":"Ioannis Androulakis ,&nbsp;Jérémy Godart ,&nbsp;Miranda E.M.C. Christianen ,&nbsp;Henrike Westerveld ,&nbsp;Lorne Luthart ,&nbsp;Remi A. Nout ,&nbsp;Mischa S. Hoogeman ,&nbsp;Inger-Karine K. Kolkman-Deurloo","doi":"10.1016/j.phro.2025.100884","DOIUrl":"10.1016/j.phro.2025.100884","url":null,"abstract":"<div><h3>Background and Purpose</h3><div>Manual transrectal ultrasound (TRUS) reconstruction, currently used in intraoperative prostate brachytherapy, is error‑prone. Automated implant reconstruction with electromagnetic tracking (EMT) has the potential to improve accuracy. The aim of this study was to implement and validate afterloader‑integrated EMT for automated implant reconstruction.</div></div><div><h3>Materials and Methods</h3><div>An afterloader prototype equipped with an integrated EMT system was used in conjunction with a TRUS-based treatment planning system and setup. A workflow was developed to transform the EMT measurements into the implant reconstruction and import this into the treatment planning software. The workflow was retrospectively evaluated using clinical data from 14 patients. To align the EMT measurements with the treatment-planning coordinate system without a TRUS-based pre-reconstruction, a novel setup was developed using a single reference sensor integrated into the template holder. The reproducibility and accuracy of the workflow using this latter setup was evaluated in phantom measurements.</div></div><div><h3>Results</h3><div>The retrospective evaluation revealed that errors in active dwell positions of up to 10.2 mm caused absolute V<sub>100%</sub> differences of up to 5.3 % of the target volume, and up to 24.4 %, 2.1 %, and 14.1 % of the prescribed dose for urethra D<sub>0.1cm</sub><sub>3</sub>, rectum D<sub>2cm3</sub>, and bladder D<sub>1cm3</sub>, respectively. In phantom measurements with our novel setup using reference sensor registration, EMT-based reconstruction demonstrated high reproducibility (0.5 mm) and agreement with TRUS-based reconstruction (0.7 mm), requiring a measurement time of &lt; 23 s per implanted needle.</div></div><div><h3>Conclusion</h3><div>The implementation of EMT-based reconstruction on clinical data shows clinically relevant impact on dose-volume metrics of TRUS-based implant reconstructions errors. Using the novel workflow and hardware, highly accurate and automated implant reconstruction is possible.</div></div>","PeriodicalId":36850,"journal":{"name":"Physics and Imaging in Radiation Oncology","volume":"36 ","pages":"Article 100884"},"PeriodicalIF":3.3,"publicationDate":"2025-10-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145681027","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Individualised dose mapping uncertainty estimation in the reirradiation setting 再照射环境下个体化剂量图不确定度估计
IF 3.3 Q2 ONCOLOGY Pub Date : 2025-10-01 DOI: 10.1016/j.phro.2025.100881
Chelmis Muthoni Thiong’o , Marcel van Herk , Kathryn Banfill , Clara Chan , Catherine Harris , Matthew Lowe , Tom Marchant , Iskandar Mohamed , Golnoosh Motamedi-Ghahfarokhi , David Thomson , Ane Appelt , Eliana Vasquez Osorio

Background and purpose

Deformable image registration (DIR) allows assessing radiation doses of previous treatment courses in reirradiation planning scans. However, DIR can introduce uncertainties in dose mapping. Estimating these uncertainties for individual patients remains a key challenge. We developed an individualised approach to estimate uncertainties in dose mapping using a commercially available treatment planning system.

Materials and methods

For 54 patients who underwent reirradiation (27 head and neck, H&N, and 27 lung cases), we performed 16 DIRs per patient. We assessed each DIR geometrically using the mean distance to agreement (mDTA) between mapped contours and the corresponding structures of 30 to 34 organs at risk (OARs). We then estimated dose mapping uncertainties for structures where DIR resulted in plausible registrations, defined as mDTA ≤ 0.3 cm. We calculated the uncertainty of dose-volume-histogram estimates (mean and D0.1 cm3) and voxel-wise uncertainties using standard deviation (SD). We also tested the impact of using fewer registrations.

Results

DIR resulted in plausible mappings for both patient cohorts’ OARs, ranging between 78.6 % and 88.2 %, varying between patients and OARs. Mean dose uncertainties ranged between 0 Gy and 0.43 Gy, while larger differences were observed for D0.1 cm3, between 0 Gy and 0.78 Gy. As expected, large voxel-wise uncertainties were in regions of steep dose gradients. Performance between registration sets was similar.

Conclusion

We developed a method to estimate dose mapping uncertainties with integrated quality control for reirradiation. Differences between patients were observed, justifying the need for individualised DIR assessment. Few registrations were a pragmatic approach.
背景和目的形变图像配准(DIR)允许在再照射计划扫描中评估先前治疗过程的辐射剂量。然而,DIR可能在剂量图中引入不确定性。估计个别患者的这些不确定性仍然是一个关键的挑战。我们开发了一种个性化的方法,使用市售的治疗计划系统来估计剂量图中的不确定性。材料和方法对54例接受再照射的患者(27例头颈部、H&;N和27例肺部),我们对每位患者进行了16次DIRs。我们使用30至34个危险器官(OARs)的绘制轮廓线与相应结构之间的平均一致距离(mDTA)对每个DIR进行几何评估。然后,我们估计了DIR导致合理配准的结构的剂量映射不确定性,定义为mDTA≤0.3 cm。我们计算了剂量-体积-直方图估计的不确定性(平均值和D0.1 cm3)和使用标准差(SD)的体素不确定性。我们还测试了使用更少注册的影响。结果dir对两组患者的桨位进行了合理的映射,范围在78.6%到88.2%之间,在患者和桨位之间有所不同。平均剂量不确定性介于0 Gy和0.43 Gy之间,而D0.1 cm3的差异更大,介于0 Gy和0.78 Gy之间。正如预期的那样,在剂量梯度较大的区域存在较大的体素不确定性。注册集之间的性能是相似的。结论建立了一种综合质量控制的剂量图不确定度估算方法。观察到患者之间的差异,证明了个体化DIR评估的必要性。很少注册是一种务实的方法。
{"title":"Individualised dose mapping uncertainty estimation in the reirradiation setting","authors":"Chelmis Muthoni Thiong’o ,&nbsp;Marcel van Herk ,&nbsp;Kathryn Banfill ,&nbsp;Clara Chan ,&nbsp;Catherine Harris ,&nbsp;Matthew Lowe ,&nbsp;Tom Marchant ,&nbsp;Iskandar Mohamed ,&nbsp;Golnoosh Motamedi-Ghahfarokhi ,&nbsp;David Thomson ,&nbsp;Ane Appelt ,&nbsp;Eliana Vasquez Osorio","doi":"10.1016/j.phro.2025.100881","DOIUrl":"10.1016/j.phro.2025.100881","url":null,"abstract":"<div><h3>Background and purpose</h3><div>Deformable image registration (DIR) allows assessing radiation doses of previous treatment courses in reirradiation planning scans. However, DIR can introduce uncertainties in dose mapping. Estimating these uncertainties for individual patients remains a key challenge. We developed an individualised approach to estimate uncertainties in dose mapping using a commercially available treatment planning system.</div></div><div><h3>Materials and methods</h3><div>For 54 patients who underwent reirradiation (27 head and neck, H&amp;N, and 27 lung cases), we performed 16 DIRs per patient. We assessed each DIR geometrically using the mean distance to agreement (mDTA) between mapped contours and the corresponding structures of 30 to 34 organs at risk (OARs). We then estimated dose mapping uncertainties for structures where DIR resulted in plausible registrations, defined as mDTA ≤ 0.3 cm. We calculated the uncertainty of dose-volume-histogram estimates (mean and D0.1 cm<sup>3</sup>) and voxel-wise uncertainties using standard deviation (SD). We also tested the impact of using fewer registrations.</div></div><div><h3>Results</h3><div>DIR resulted in plausible mappings for both patient cohorts’ OARs, ranging between 78.6 % and 88.2 %, varying between patients and OARs. Mean dose uncertainties ranged between 0 Gy and 0.43 Gy, while larger differences were observed for D0.1 cm3, between 0 Gy and 0.78 Gy. As expected, large voxel-wise uncertainties were in regions of steep dose gradients. Performance between registration sets was similar.</div></div><div><h3>Conclusion</h3><div>We developed a method to estimate dose mapping uncertainties with integrated quality control for reirradiation. Differences between patients were observed, justifying the need for individualised DIR assessment. Few registrations were a pragmatic approach.</div></div>","PeriodicalId":36850,"journal":{"name":"Physics and Imaging in Radiation Oncology","volume":"36 ","pages":"Article 100881"},"PeriodicalIF":3.3,"publicationDate":"2025-10-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145681033","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Triggered plan adaptation using multi-image optimization for improved robustness in head-and-neck cancer proton therapy 基于多图像优化的触发计划自适应提高头颈癌质子治疗的鲁棒性
IF 3.3 Q2 ONCOLOGY Pub Date : 2025-10-01 DOI: 10.1016/j.phro.2025.100871
Nadine Vatterodt , Brian Winey , Stine S. Korreman

Background and purpose

Anatomical variations in head-and-neck (HNC) proton therapy may degrade target coverage and organ-at-risk (OAR) sparing. This study introduces a triggered robust adaptation strategy utilizing multi-image optimization to progressively enhance plan robustness guided by observed dose deviations for targets and OARs.

Material and methods

Five oropharyngeal cancer patients treated with proton therapy were retrospectively analyzed. Synthetic computed tomography (CT) scans were generated from daily cone-beam CTs for dose recalculation. Four strategies were compared: no adaptation (NA), triggered adaptation without anatomical robustness (TA), and triggered robust adaptation using single (TRA-S) or multiple (TRA-M) triggered fraction images. Adaptation was triggered by exceeded thresholds in dose-volume metric deviations. Treatment strategies were evaluated by comparing target coverage, OAR dose, integral dose and number of threshold violations.

Results

TRA-S and TRA-M consistently improved target coverage up to +0.76 Gy in median D98% vs. NA, with fewer threshold violations (5 and 4) compared to NA and TA (both 8). Larger unfavorable dose deviations were reduced, with OAR doses generally comparable to NA. TA maintained OAR doses closer to the planned values, while not improving target coverage in all cases. Integral dose increased with TRA strategies up to 3.7 Gy·L compared to NA. Differences between TRA-S and TRA-M were generally small.

Conclusion

Triggered robust adaptation balanced target coverage and OAR sparing, while requiring fewer adaptations compared to triggered adaptation without anatomical robustness. It offers a potential pathway for implementing anatomical robust optimization in HNC proton therapy without relying on predicted images or additional CT scans.
背景与目的头颈部(HNC)质子治疗的解剖差异可能降低靶覆盖和危险器官(OAR)的保留。本研究引入了一种触发型鲁棒自适应策略,利用多图像优化,在观测到的剂量偏差指导下逐步增强目标和桨的计划鲁棒性。材料与方法对5例经质子治疗的口咽癌患者进行回顾性分析。合成计算机断层扫描(CT)扫描由每日锥形束CT生成,用于剂量重新计算。比较了四种策略:无适应性(NA)、触发适应性(TA)和触发适应性(单个(TRA-S)或多个(TRA-M)触发分数图像)。适应是在剂量-体积度量偏差超过阈值时触发的。通过比较靶覆盖率、OAR剂量、积分剂量和阈值违规次数来评估治疗策略。结果与NA相比,tra - s和TRA-M在中位D98%中持续提高目标覆盖率,最高可达+0.76 Gy,与NA和TA(均为8)相比,阈值违规(5和4)较少。较大的不利剂量偏差减少,OAR剂量通常与NA相当。TA维持桨叶剂量更接近计划值,但没有在所有情况下提高目标覆盖率。与NA相比,TRA策略的整体剂量增加至3.7 Gy·L。TRA-S和TRA-M之间的差异一般较小。与没有解剖稳健性的触发适应相比,触发适应需要更少的适应,同时平衡了目标覆盖和桨叶保护。它为HNC质子治疗中实现解剖学稳健优化提供了潜在途径,而无需依赖于预测图像或额外的CT扫描。
{"title":"Triggered plan adaptation using multi-image optimization for improved robustness in head-and-neck cancer proton therapy","authors":"Nadine Vatterodt ,&nbsp;Brian Winey ,&nbsp;Stine S. Korreman","doi":"10.1016/j.phro.2025.100871","DOIUrl":"10.1016/j.phro.2025.100871","url":null,"abstract":"<div><h3>Background and purpose</h3><div>Anatomical variations in head-and-neck (HNC) proton therapy may degrade target coverage and organ-at-risk (OAR) sparing. This study introduces a triggered robust adaptation strategy utilizing multi-image optimization to progressively enhance plan robustness guided by observed dose deviations for targets and OARs.</div></div><div><h3>Material and methods</h3><div>Five oropharyngeal cancer patients treated with proton therapy were retrospectively analyzed. Synthetic computed tomography (CT) scans were generated from daily cone-beam CTs for dose recalculation. Four strategies were compared: no adaptation (<em>NA</em>), triggered adaptation without anatomical robustness (<em>TA</em>), and triggered robust adaptation using single (<em>TRA-S</em>) or multiple (<em>TRA-M</em>) triggered fraction images. Adaptation was triggered by exceeded thresholds in dose-volume metric deviations. Treatment strategies were evaluated by comparing target coverage, OAR dose, integral dose and number of threshold violations.</div></div><div><h3>Results</h3><div><em>TRA-S</em> and <em>TRA-M</em> consistently improved target coverage up to +0.76 Gy in median D<sub>98%</sub> vs. <em>NA</em>, with fewer threshold violations (5 and 4) compared to <em>NA</em> and <em>TA</em> (both 8). Larger unfavorable dose deviations were reduced, with OAR doses generally comparable to NA. <em>TA</em> maintained OAR doses closer to the planned values, while not improving target coverage in all cases. Integral dose increased with <em>TRA</em> strategies up to 3.7 Gy·L compared to <em>NA</em>. Differences between <em>TRA-S</em> and <em>TRA-M</em> were generally small.</div></div><div><h3>Conclusion</h3><div>Triggered robust adaptation balanced target coverage and OAR sparing, while requiring fewer adaptations compared to triggered adaptation without anatomical robustness. It offers a potential pathway for implementing anatomical robust optimization in HNC proton therapy without relying on predicted images or additional CT scans.</div></div>","PeriodicalId":36850,"journal":{"name":"Physics and Imaging in Radiation Oncology","volume":"36 ","pages":"Article 100871"},"PeriodicalIF":3.3,"publicationDate":"2025-10-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145681034","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Integrating spot-scanning proton arc therapy with functional avoidance strategies to reduce pulmonary toxicity 将点扫描质子弧治疗与功能回避策略相结合,降低肺毒性
IF 3.3 Q2 ONCOLOGY Pub Date : 2025-10-01 DOI: 10.1016/j.phro.2025.100876
Yingxuan Chen , Peilin Liu , Xiaoda Cong , Edward Castillo , Richard Castillo , Inga Grills , Craig Stevens , Xiangkun Xu , Xiaoqiang Li , Yevgeniy Vinogradskiy , Xuanfeng Ding

Background and purpose

Functional avoidance radiotherapy has emerged as a promising technique using functional imaging to minimize pulmonary toxicity by reducing doses to functional lung. This study aims to investigate the potential dose-volume advantages of a novel spot-scanning proton arc (SPArc) therapy for functional avoidance radiotherapy with four-dimensional computed tomography (4DCT)-based ventilation imaging.

Material and methods

Twenty-five patients from a prospective functional avoidance clinical trial treated with intensity-modulated photon radiotherapy were included. Robustly optimized intensity modulated proton therapy (IMPT) and SPArc plans were generated in RayStation. Functional lung contour was derived from the 4DCT-based ventilation imaging and utilized as an optimization structure in photon as well as IMPT and SPArc functional planning. The dose distributions were compared, and normal tissue complication probability (NTCP) models were applied to estimate the probability of pulmonary toxicity.

Results

Using clinical photon plans as the baseline for comparison, both proton plans achieved equivalent target coverage and reduced dose to organs at risk. Compared with photon plans, the median absolute reduction of fV20Gy (the volume of functional lung receiving ≥ 20 Gy) was 3.7 percentage points (pp) with IMPT and 13.0 pp with SPArc. Using fV20Gy for NTCP estimation, the median reduction of probability of grade ≥ 2 pneumonitis was 5.0 pp with IMPT and was 14.9 pp with SPArc.

Conclusions

Our study highlighted the potential of SPArc to spare dose to functional lung. NTCP results further indicated that the risk of pulmonary complications can be reduced with SPArc compared to photon or IMPT for functional avoidance radiotherapy.
背景和目的功能回避放射治疗已成为一种很有前途的技术,利用功能成像通过减少对功能肺的剂量来减少肺毒性。本研究旨在探讨基于四维计算机断层扫描(4DCT)通气成像的新型点扫描质子弧(SPArc)治疗功能回避放疗的潜在剂量-体积优势。材料与方法采用调强光子放射治疗的前瞻性功能回避临床试验患者25例。在RayStation中生成稳健优化的强度调制质子治疗(IMPT)和SPArc计划。基于4dct的通气成像得到肺功能轮廓,并将其作为光子、IMPT和SPArc功能规划的优化结构。比较剂量分布,应用正常组织并发症概率(NTCP)模型估计肺毒性的概率。结果以临床光子治疗方案为对照,两种质子治疗方案均达到了相同的靶覆盖范围,并减少了危及器官的剂量。与光子计划相比,IMPT组fV20Gy(接受≥20Gy的功能肺体积)的中位数绝对减少3.7个百分点(pp), SPArc组为13.0个百分点。使用fV20Gy进行NTCP估计,IMPT组≥2级肺炎的概率降低中位数为5.0 pp, SPArc组为14.9 pp。结论sour研究强调了SPArc对功能性肺的备用剂量潜力。NTCP结果进一步表明,与光子或IMPT相比,SPArc可降低肺并发症的风险。
{"title":"Integrating spot-scanning proton arc therapy with functional avoidance strategies to reduce pulmonary toxicity","authors":"Yingxuan Chen ,&nbsp;Peilin Liu ,&nbsp;Xiaoda Cong ,&nbsp;Edward Castillo ,&nbsp;Richard Castillo ,&nbsp;Inga Grills ,&nbsp;Craig Stevens ,&nbsp;Xiangkun Xu ,&nbsp;Xiaoqiang Li ,&nbsp;Yevgeniy Vinogradskiy ,&nbsp;Xuanfeng Ding","doi":"10.1016/j.phro.2025.100876","DOIUrl":"10.1016/j.phro.2025.100876","url":null,"abstract":"<div><h3>Background and purpose</h3><div>Functional avoidance radiotherapy has emerged as a promising technique using functional imaging to minimize pulmonary toxicity by reducing doses to functional lung. This study aims to investigate the potential dose-volume advantages of a novel spot-scanning proton arc (SPArc) therapy for functional avoidance radiotherapy with four-dimensional computed tomography (4DCT)-based ventilation imaging.</div></div><div><h3>Material and methods</h3><div>Twenty-five patients from a prospective functional avoidance clinical trial treated with intensity-modulated photon radiotherapy were included. Robustly optimized intensity modulated proton therapy (IMPT) and SPArc plans were generated in RayStation. Functional lung contour was derived from the 4DCT-based ventilation imaging and utilized as an optimization structure in photon as well as IMPT and SPArc functional planning. The dose distributions were compared, and normal tissue complication probability (NTCP) models were applied to estimate the probability of pulmonary toxicity.</div></div><div><h3>Results</h3><div>Using clinical photon plans as the baseline for comparison, both proton plans achieved equivalent target coverage and reduced dose to organs at risk. Compared with photon plans, the median absolute reduction of fV<sub>20Gy</sub> (the volume of functional lung receiving ≥ 20 Gy) was 3.7 percentage points (pp) with IMPT and 13.0 pp with SPArc. Using fV<sub>20Gy</sub> for NTCP estimation, the median reduction of probability of grade ≥ 2 pneumonitis was 5.0 pp with IMPT and was 14.9 pp with SPArc.</div></div><div><h3>Conclusions</h3><div>Our study highlighted the potential of SPArc to spare dose to functional lung. NTCP results further indicated that the risk of pulmonary complications can be reduced with SPArc compared to photon or IMPT for functional avoidance radiotherapy.</div></div>","PeriodicalId":36850,"journal":{"name":"Physics and Imaging in Radiation Oncology","volume":"36 ","pages":"Article 100876"},"PeriodicalIF":3.3,"publicationDate":"2025-10-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145681096","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
期刊
Physics and Imaging in Radiation Oncology
全部 Acc. Chem. Res. ACS Applied Bio Materials ACS Appl. Electron. Mater. ACS Appl. Energy Mater. ACS Appl. Mater. Interfaces ACS Appl. Nano Mater. ACS Appl. Polym. Mater. ACS BIOMATER-SCI ENG ACS Catal. ACS Cent. Sci. ACS Chem. Biol. ACS Chemical Health & Safety ACS Chem. Neurosci. ACS Comb. Sci. ACS Earth Space Chem. ACS Energy Lett. ACS Infect. Dis. ACS Macro Lett. ACS Mater. Lett. ACS Med. Chem. Lett. ACS Nano ACS Omega ACS Photonics ACS Sens. ACS Sustainable Chem. Eng. ACS Synth. Biol. Anal. Chem. BIOCHEMISTRY-US Bioconjugate Chem. BIOMACROMOLECULES Chem. Res. Toxicol. Chem. Rev. Chem. Mater. CRYST GROWTH DES ENERG FUEL Environ. Sci. Technol. Environ. Sci. Technol. Lett. Eur. J. Inorg. Chem. IND ENG CHEM RES Inorg. Chem. J. Agric. Food. Chem. J. Chem. Eng. Data J. Chem. Educ. J. Chem. Inf. Model. J. Chem. Theory Comput. J. Med. Chem. J. Nat. Prod. J PROTEOME RES J. Am. Chem. Soc. LANGMUIR MACROMOLECULES Mol. Pharmaceutics Nano Lett. Org. Lett. ORG PROCESS RES DEV ORGANOMETALLICS J. Org. Chem. J. Phys. Chem. J. Phys. Chem. A J. Phys. Chem. B J. Phys. Chem. C J. Phys. Chem. Lett. Analyst Anal. Methods Biomater. Sci. Catal. Sci. Technol. Chem. Commun. Chem. Soc. Rev. CHEM EDUC RES PRACT CRYSTENGCOMM Dalton Trans. Energy Environ. Sci. ENVIRON SCI-NANO ENVIRON SCI-PROC IMP ENVIRON SCI-WAT RES Faraday Discuss. Food Funct. Green Chem. Inorg. Chem. Front. Integr. Biol. J. Anal. At. Spectrom. J. Mater. Chem. A J. Mater. Chem. B J. Mater. Chem. C Lab Chip Mater. Chem. Front. Mater. Horiz. MEDCHEMCOMM Metallomics Mol. Biosyst. Mol. Syst. Des. Eng. Nanoscale Nanoscale Horiz. Nat. Prod. Rep. New J. Chem. Org. Biomol. Chem. Org. Chem. Front. PHOTOCH PHOTOBIO SCI PCCP Polym. Chem.
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
0
微信
客服QQ
Book学术公众号 扫码关注我们
反馈
×
意见反馈
请填写您的意见或建议
请填写您的手机或邮箱
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
现在去查看 取消
×
提示
确定
Book学术官方微信
Book学术文献互助
Book学术文献互助群
群 号:604180095
Book学术
文献互助 智能选刊 最新文献 互助须知 联系我们:info@booksci.cn
Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。
Copyright © 2023 Book学术 All rights reserved.
ghs 京公网安备 11010802042870号 京ICP备2023020795号-1